PubMed Health⌕ Search

PubMed · 11101921

Percolation parameter and percolation-threshold estimates for three-dimensional random ellipses with widely scattered distributions of eccentricity and size

Abstract

In fractured materials of very low matrix permeability, fracture connectivity is the first-order determinant of the occurrence of flow. For systems having a narrow distribution of object sizes (short-range percolation), a first-order percolation criterion is given by the total excluded volume which is almost constant at threshold. In the case of fractured media, recent observations have demonstrated that the fracture-length distribution is extremely large. Because of this widely scattered fracture-length distribution, the classical expression of the total excluded volume is no longer scale invariant at the percolation threshold and has no finite limit for infinitely large systems. Thus, the classical estimation method of the percolation threshold established in short-range percolation becomes useless for the connectivity determination of fractured media. In this study, we derive an expression for the total excluded volume that remains scale invariant at the percolation threshold and that can thus be used as the proper control parameter, called the parameter of percolation in percolation theory. We show that the scale-invariant expression of the total excluded volume is the geometrical union normalized by the system volume rather than the summation of the mutual excluded volumes normalized by the system volume. The summation of the mutual excluded volume (classical expression) remains linked to the number of intersections between fractures, whereas the normalized geometrical union of the mutual excluded volume (our expression) can be essentially identified with the percolation parameter. Moreover, fluctuations of this percolation parameter at threshold with length and eccentricity distributions remain limited within a range of less than one order of magnitude, giving in turn a rough percolation criterion. We finally show that the scale dependence of the percolation parameter causes the connectivity of fractured media to increase with scale, meaning especially that the hydraulic properties of fractured media can dramatically change with scale.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J R de Dreuzy, P Davy, O Bour. 2000. Percolation parameter and percolation-threshold estimates for three-dimensional random ellipses with widely scattered distributions of eccentricity and size. https://doi.org/10.1103/physreve.62.5948

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗